Britain and America have agreed to a major bilateral deal that will preserve no tariffs on UK drug exports going into the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has pledged to boost expenditure on pharmaceuticals through the public health system. This pledge secures that import taxes on these crucial products will be held at zero for a timeframe of the next three years.
This agreement is in response to earlier statements to significantly raise tariffs on patented pharmaceutical products, with potential rates floated as high as double the cost.
"This agreement with the Britain strengthens the global environment for cutting-edge drugs and introduces long-overdue fairness to American-British medicine commerce," a statement noted.
Commercial Impact
Pharmaceuticals constitute one of the UK's most significant goods shipped to the United States, which is by far the primary buyer for large UK drugmakers.
Trade data reveal that in the year to the end of last September, the UK exported drugs valued at £11.1bn to the US. This figure made up a significant portion of British export trade in that period.
"This guarantee protects jobs, boosts funding and facilitates the UK to become a international leader for life sciences," a government official remarked.
Specific British Pledges
The pact involves several specific pledges from the British government:
- Price Threshold Increase: The UK will increase the price threshold at which it deems new medicines to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a aim to double overall health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The percentage drug companies must pay back to the NHS to stay within budget will be capped at fifteen percent. Last year, refunds exceeded 20%.
Recent Tensions
The pact takes place against a long-running tension between the pharmaceutical industry and the ministers over drug pricing and approval rates.
This friction were heightened by claims that American patients were charged a premium for the identical medicines than people in the other developed nations.
Over the last 18 months, several major pharmaceutical investments in the UK have been delayed or abandoned, while multi-billion-dollar funding commitments have been directed toward American operations.
The Science Minister acknowledged that the NHS must invest a greater share on medicines, noting that its spending on drugs had declined as a proportion of its total funding over the last ten years.
